Letermovir Reduces Chronic GVHD Risk in Calcineurin Inhibitor-free GVHD Prophylaxis After Hematopoietic Cell Transplantation

Lonnqvist B, Ringden O, Wahren B, Gahrton G, Lundgren G . Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation. 1984; 38(5):465-8. DOI: 10.1097/00007890-198411000-00004. View

Alousi A, Brammer J, Saliba R, Andersson B, Popat U, Hosing C . Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant. 2015; 21(5):906-12. PMC: 4825327. DOI: 10.1016/j.bbmt.2015.01.026. View

Bradstock K, Bilmon I, Kwan J, Micklethwaite K, Blyth E, Deren S . Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen-Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host.... Biol Blood Marrow Transplant. 2015; 21(5):941-4. DOI: 10.1016/j.bbmt.2015.01.020. View

Terao T, Matsuoka K, Narita K, Tsushima T, Yuyama S, Kuzume A . Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft--Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide. Front Oncol. 2021; 11:666774. PMC: 8117228. DOI: 10.3389/fonc.2021.666774. View

Rosenbaum P, Rubin D . The bias due to incomplete matching. Biometrics. 1985; 41(1):103-16. View

LeGoff J, Michonneau D, Socie G . The virome in hematology-Stem cell transplantation and beyond. Semin Hematol. 2020; 57(1):19-25. DOI: 10.1053/j.seminhematol.2020.05.001. View

Palaniyandi S, Radhakrishnan S, Karlsson F, Stokes K, Kittan N, Huber E . Murine cytomegalovirus immediate-early 1 gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from latent infection. PLoS One. 2013; 8(4):e61841. PMC: 3626592. DOI: 10.1371/journal.pone.0061841. View

Olkinuora H, Willebrand E, Kantele J, Vainio O, Talvensaari K, Saarinen-Pihkala U . The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation. Scand J Immunol. 2011; 73(6):586-93. DOI: 10.1111/j.1365-3083.2011.02530.x. View

Kanakry C, Tsai H, Bolanos-Meade J, Smith B, Gojo I, Kanakry J . Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014; 124(25):3817-27. PMC: 4263989. DOI: 10.1182/blood-2014-07-587477. View

10.

Ghobadi A, Milton D, Gowda L, Rondon G, Chemaly R, Hamdi A . HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Curr Res Transl Med. 2019; 67(2):51-55. PMC: 7735254. DOI: 10.1016/j.retram.2019.01.001. View

11.

Goldsmith S, Slade M, Dipersio J, Westervelt P, Lawrence S, Uy G . Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. Haematologica. 2016; 101(11):e465-e468. PMC: 5394884. DOI: 10.3324/haematol.2016.149880. View

12.

Greco R, Lorentino F, Albanese S, Lupo Stanghellini M, Giglio F, Piemontese S . Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. Transplant Cell Ther. 2021; 27(9):776.e1-776.e13. DOI: 10.1016/j.jtct.2021.05.023. View

13.

Goldsmith S, Abid M, Auletta J, Bashey A, Beitinjaneh A, Castillo P . Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021; 137(23):3291-3305. PMC: 8351903. DOI: 10.1182/blood.2020009362. View

14.

Ljungman P, Schmitt M, Marty F, Maertens J, Chemaly R, Kartsonis N . A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation. Clin Infect Dis. 2019; 70(8):1525-1533. PMC: 7146004. DOI: 10.1093/cid/ciz490. View

15.

Oltolini C, Greco R, Galli L, Clerici D, Lorentino F, Xue E . Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. Biol Blood Marrow Transplant. 2020; 26(6):1179-1188. DOI: 10.1016/j.bbmt.2020.01.013. View

16.

de Wreede L, Fiocco M, Putter H . The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. Comput Methods Programs Biomed. 2010; 99(3):261-74. DOI: 10.1016/j.cmpb.2010.01.001. View

17.

Mulroney C, Abid M, Bashey A, Chemaly R, Ciurea S, Chen M . Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation. Br J Haematol. 2021; 194(1):145-157. PMC: 8853845. DOI: 10.1111/bjh.17563. View

18.

Irene G, Albert E, Anna B, Rahinatu A, Silvana N, Silvana S . Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching. Bone Marrow Transplant. 2020; 56(4):818-827. PMC: 7587539. DOI: 10.1038/s41409-020-01092-x. View

19.

Kanakry C, Bolanos-Meade J, Kasamon Y, Zahurak M, Durakovic N, Furlong T . Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood. 2017; 129(10):1389-1393. PMC: 5345732. DOI: 10.1182/blood-2016-09-737825. View

20.

Cantoni N, Hirsch H, Khanna N, Gerull S, Buser A, Bucher C . Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010; 16(9):1309-14. DOI: 10.1016/j.bbmt.2010.03.020. View